Yarrow Bioscience, Inc. (YARW)
40.67
+1.42
(+3.62%)
USD |
NASDAQ |
Aug 26, 10:09
Yarrow Bioscience EPS Diluted (Quarterly) : -3.504 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -3.504 |
| March 31, 2026 | -4.191 |
| December 31, 2025 | -7.258 |
| September 30, 2025 | -8.504 |
| June 30, 2025 | -6.730 |
| March 31, 2025 | -10.09 |
| December 31, 2024 | -14.11 |
| September 30, 2024 | -0.2855 |
| June 30, 2024 | -0.2206 |
| March 31, 2024 | -0.1466 |
| December 31, 2023 | -0.1993 |
| September 30, 2023 | -2.006 |
| June 30, 2023 | -3.072 |
| March 31, 2023 | -1.724 |
| December 31, 2022 | -3.332 |
| September 30, 2022 | -2.912 |
| June 30, 2022 | -2.634 |
| March 31, 2022 | -2.709 |
| December 31, 2021 | -194.52 |
| September 30, 2021 | -368.20 |
| Date | Value |
|---|---|
| June 30, 2021 | -348.79 |
| March 31, 2021 | -378.47 |
| December 31, 2020 | -9.880 |
| September 30, 2020 | -10.61 |
| June 30, 2020 | -86.95 |
| March 31, 2020 | -68.14 |
| December 31, 2019 | -3750.34 |
| September 30, 2019 | -827.14 |
| June 30, 2019 | -697.72 |
| March 31, 2019 | -1699.34 |
| December 31, 2018 | -54.68 |
| September 30, 2018 | -40.26 |
| June 30, 2018 | -26.28 |
| March 31, 2018 | -51.83 |
| December 31, 2017 | -29.07 |
| September 30, 2017 | -25.61 |
| June 30, 2017 | -19.28 |
| March 31, 2017 | -17.15 |
| December 31, 2016 | -15.16 |
| September 30, 2016 | -10.65 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Oramed Pharmaceuticals, Inc. | 1.839 |
| NRX Pharmaceuticals, Inc. | -0.4388 |
| ANI Pharmaceuticals, Inc. | 1.052 |
| Corcept Therapeutics, Inc. | 0.356 |
| Veru, Inc. | -0.3032 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -2.899M |
| Revenue (Quarterly) | 0.097M |
| Total Expenses (Quarterly) | 2.996M |
| Enterprise Value | 3.306M |
| Gross Profit Margin (Quarterly) | 93.81% |
| Profit Margin (Quarterly) | -2.99K% |
| Earnings Yield | -57.68% |
| Normalized Earnings Yield | -57.68 |